A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 22, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions

Primary Sclerosing Cholangitis

Interventions

DRUG

DUR-928

oral suspension daily for 28 days

Trial Locations (4)

Charlotte Mecklenburg Hospital, Charlotte

Mayo Clinic Florida, Jacksonville

Southern Therapy and Advanced Research, Jackson

California Pacific Medical Center, San Francisco